Here are four things to know:
1. The drugs are intended to lower cardiovascular risk in patients with high levels of lipoproteins.
2. Carlsbad, Calif.-based Ionis and Cambridge, Mass.-based Akcea are eligible to receive $225 million in near-term payments, along with a $75 million in upfront option payment and a $100 million equity investment in Ionis, according to the report.
3. The deal is valued at more than $1 billion when including license fees, milestone payments and royalties if both drugs are successfully licensed and commercialized.
4. Basel, Switzerland-based Novartis will be responsible for the worldwide development and commercialization of both drugs, pending the completion of specific development milestones and successful trial results.
More articles on supply chain:
6 must-reads for supply chain leaders this week
10 medical device trends for 2017
Director of supply chain named one of best jobs in America by CNNMoney
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
